CN112029858B - Predictive index for tumor immunotherapy - Google Patents
Predictive index for tumor immunotherapy Download PDFInfo
- Publication number
- CN112029858B CN112029858B CN202010844019.XA CN202010844019A CN112029858B CN 112029858 B CN112029858 B CN 112029858B CN 202010844019 A CN202010844019 A CN 202010844019A CN 112029858 B CN112029858 B CN 112029858B
- Authority
- CN
- China
- Prior art keywords
- sequence
- cdr3
- tumor
- infiltrating lymphocytes
- artificial sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 title abstract description 17
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims abstract description 56
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 37
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 21
- 239000011886 peripheral blood Substances 0.000 claims abstract description 21
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims abstract description 16
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 8
- 238000012163 sequencing technique Methods 0.000 claims description 40
- 238000004364 calculation method Methods 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 abstract description 26
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 9
- 238000004393 prognosis Methods 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 108020004414 DNA Proteins 0.000 description 54
- 239000000523 sample Substances 0.000 description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 description 8
- 102000008096 B7-H1 Antigen Human genes 0.000 description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 5
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 2
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
component (A) | Volume (quality) |
2×QIAGEN Multiplex PCR Master Mix | 25μL |
5 XQ solution | 5μL |
Specific primer sets (for primer information see Table 1) | 2μL |
Sample DNA | 1ug |
NF-H 2 O | Supplement to50μL |
Total volume of | 50μL |
component (A) | Volume (mu L) |
Purification of DNA | 23 |
Primer1 public (10 uM) | 1 |
Primer Index_X(10uM) | 1 |
2×KAPA hifi hot start Master Mix | 25 |
Total volume of | 50 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010844019.XA CN112029858B (en) | 2020-08-20 | 2020-08-20 | Predictive index for tumor immunotherapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010844019.XA CN112029858B (en) | 2020-08-20 | 2020-08-20 | Predictive index for tumor immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112029858A CN112029858A (en) | 2020-12-04 |
CN112029858B true CN112029858B (en) | 2023-11-24 |
Family
ID=73580997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010844019.XA Active CN112029858B (en) | 2020-08-20 | 2020-08-20 | Predictive index for tumor immunotherapy |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112029858B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114107512B (en) * | 2022-01-26 | 2022-05-13 | 北京大学 | Early screening device for acquired drug resistance of immunotherapy and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106987631A (en) * | 2017-04-01 | 2017-07-28 | 武汉赛云博生物科技有限公司 | A kind of immune group sequencing technologies for the adjoint diagnosis of PD 1/PD L1 blocking treatments |
CN111094977A (en) * | 2017-07-13 | 2020-05-01 | 古斯塔夫·鲁西研究所 | Imaging tools based on imaging omics to monitor tumor lymphocyte infiltration and prognosis in anti-PD-1/PD-L1 treated tumor patients |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2984234C (en) * | 2015-05-01 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
-
2020
- 2020-08-20 CN CN202010844019.XA patent/CN112029858B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106987631A (en) * | 2017-04-01 | 2017-07-28 | 武汉赛云博生物科技有限公司 | A kind of immune group sequencing technologies for the adjoint diagnosis of PD 1/PD L1 blocking treatments |
CN111094977A (en) * | 2017-07-13 | 2020-05-01 | 古斯塔夫·鲁西研究所 | Imaging tools based on imaging omics to monitor tumor lymphocyte infiltration and prognosis in anti-PD-1/PD-L1 treated tumor patients |
Also Published As
Publication number | Publication date |
---|---|
CN112029858A (en) | 2020-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6966508B2 (en) | Urine biomarker cohort, gene expression characteristics, and methods of their use | |
CN113284554B (en) | Circulating tumor DNA detection system for screening micro residual focus after colorectal cancer operation and predicting recurrence risk and application | |
CN106650312B (en) | Device for detecting copy number variation of circulating tumor DNA | |
CA2553551C (en) | Methods and compositions for determining a graft tolerant phenotype in a subject | |
CN106536752A (en) | Methods of monitoring immunosuppressive therapies in transplant recipient | |
EP2909340B1 (en) | Diagnostic method for predicting response to tnf alpha inhibitor | |
CN107034301A (en) | A kind of detection Lung neoplasm is benign or pernicious kit and its application | |
CN113337613B (en) | Serum exosome tsRNA marker related to liver cancer, probe and application thereof | |
CN110564858A (en) | RT-PCR kit for predicting curative effect of immunodetection point regulation type medicines and prediction method thereof | |
WO2009156858A1 (en) | Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen | |
CN112029858B (en) | Predictive index for tumor immunotherapy | |
CN115820847A (en) | Detection reagent for methylation of cervical cancer related genes and application thereof | |
CN109055564B (en) | CircRNA marker for diagnosis and prognosis evaluation of chronic lymphocytic leukemia | |
CN108866187B (en) | Long-chain non-coding RNA marker related to lung cancer auxiliary diagnosis and application thereof | |
CN107254546B (en) | SNP marker related to breast cancer neoadjuvant chemotherapy curative effect and application thereof | |
CN113528509A (en) | Construction method of tumor microenvironment scoring system for predicting gastric cancer immunotherapy and molecular probe | |
CN111690746A (en) | Platelet RNA marker related to lung cancer and application thereof | |
CN115807084B (en) | Biomarker for predicting adverse events of blocking treatment of tumor immune checkpoints and application of biomarker | |
CN113584169B (en) | Serum tsRNA marker and probe related to liver cancer and application of serum tsRNA marker and probe | |
CA3085464A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
CN109097476B (en) | Lung cancer bone metastasis gene detection and diagnosis kit | |
CN108707548B (en) | Nonfunctional pituitary adenoma detection device and application | |
Attia et al. | Altered expression of microRNAs in the bone marrow of multiple myeloma patients and their relationship to cytogenetic aberrations | |
CN107858427B (en) | Application of miR-429 in preparation of breast cancer diagnosis and detection kit | |
CN110541034B (en) | Application of LINC01992 in breast cancer diagnosis and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Guan Yanfang Inventor after: Li Jin Inventor after: Zhang Chunliu Inventor after: Xu Yaping Inventor after: Yi Xin Inventor after: Wang Yuqi Inventor after: Yang Ling Inventor before: Guan Yanfang Inventor before: Xu Yaping Inventor before: Zhang Chunliu Inventor before: Li Jin Inventor before: Yi Xin Inventor before: Wang Yuqi Inventor before: Yang Ling |
|
GR01 | Patent grant | ||
GR01 | Patent grant |